Acasti Pharma Inc. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported net loss was USD 42.43 million compared to USD 9.82 million a year ago. Basic loss per share from continuing operations was USD 5.7 compared to USD 1.62 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.68 USD | -7.59% | -5.96% | -7.27% |
Feb. 12 | Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
Feb. 07 | Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.27% | 25.19M | |
+26.47% | 664B | |
+29.72% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+14.26% | 234B | |
+4.94% | 199B | |
-10.06% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- ACST Stock
- News Acasti Pharma Inc.
- Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2023